1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Cardiac Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amuzie, C; Bedja, D; Bhattacharya, R; Chatterjee, S; Foss, CA; Mishra, S; Pomper, MG; Yarema, KJ | 1 |
| Amuzie, C; Avolio, A; Bedja, D; Chatterjee, S; Mishra, S | 1 |
2 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Cardiac Hypertrophy
| Article | Year |
|---|---|
Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Capsules; Cardiomegaly; Cholesterol, Dietary; Decanoic Acids; Delayed-Action Preparations; Dicarboxylic Acids; Diet, Atherogenic; Drug Evaluation, Preclinical; Heart Ventricles; Inactivation, Metabolic; Iodine Radioisotopes; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Morpholines; Nanoparticles; Polyethylene Glycols; Tissue Distribution; Vascular Stiffness | 2015 |
Prevention of cardiac hypertrophy by the use of a glycosphingolipid synthesis inhibitor in ApoE-/- mice.
Topics: Animals; Apolipoproteins E; Atrial Natriuretic Factor; Cardiomegaly; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Enzyme Inhibitors; Galactosyltransferases; Gene Expression; Glucosyltransferases; Glycosphingolipids; Heart Ventricles; Male; Mice; Mice, Knockout; Mitogen-Activated Protein Kinases; Morpholines; Myocytes, Cardiac; Natriuretic Peptide, Brain; Phosphorylation | 2015 |